Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Alles Lungenkrebs? : Hasenpest als seltene DifferenzialdiagnoseIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Jg. 197, 2025, Nr. 12, S. 1440 – 1441
-
Automated 3D-Body Composition Analysis as a Predictor of Survival in Patients with Idiopathic Pulmonary FibrosisIn: Journal of Thoracic Imaging, Jg. 40, 2025, Nr. 2, e0803DOI (Open Access)
-
Challenges in diagnosis of sarcoidosisIn: Current Opinion in Immunology, Jg. 97, 2025, 102652DOI (Open Access)
-
Childhood interstitial lung disease survivors in adulthood: a European collaborative studyIn: European Respiratory Journal (ERJ), Jg. 65, 2025, Nr. 2, 2400680
-
Clinical Characteristics of Anti-Synthetase Syndrome : Analysis From the Classification Criteria for Anti-Synthetase Syndrome ProjectIn: Arthritis & Rheumatology, Jg. 77, 2025, Nr. 4, S. 477 – 489DOI (Open Access)
-
Consensus nomenclature and abbreviation for anti-synthetase syndrome : An IMACS projectIn: Rheumatology, Jg. 64, 2025, Nr. 9, S. 4930 – 4936
-
Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis : Data from INBUILD-ONIn: Lung, Jg. 203, 2025, Nr. 1, 25DOI (Open Access)
-
Correction: Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosisIn: Frontiers in Medicine, Jg. 12, 2025, 1654729DOI (Open Access)
-
Pulmonary sarcoidosis clinical trial end-points : A Delphi studyIn: European Respiratory Journal (ERJ), Jg. 66, 2025, Nr. 4, 2500943
-
Real-life characteristics and management of patients with fibrosing interstitial lung disease : INSIGHTS-ILD registryIn: ERJ Open Research, Jg. 11, 2025, Nr. 3, 00926-2024DOI (Open Access)
-
Recurrent pulmonary alveolar proteinosis after lung transplantation : A case seriesIn: Respiratory Medicine, Jg. 244, 2025, 108167DOI (Open Access)
-
Sandsturm in der Lunge : Pulmonale alveoläre MikrolithiasisIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2025
-
Serum KL-6 as a biomarker to predict progression at one year in interstitial lung diseaseIn: Scientific Reports, Jg. 15, 2025, Nr. 1, 35243DOI (Open Access)
-
Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosisIn: Frontiers in Medicine, Jg. 12, 2025, 1579209DOI (Open Access)
-
Stratifying GAP Stages by MUC5B rs35705950 T-Allele Carriage Refines Survival Prediction in IPFIn: Lung, Jg. 203, 2025, Nr. 1, 85DOI (Open Access)
-
The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the artIn: European Respiratory Review (ERR), Jg. 34, 2025, Nr. 175, 240147DOI, Online Volltext (Open Access)
-
The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome : analysis from the CLASS projectIn: Annals of the Rheumatic Diseases (ARD), Jg. 84, 2025, Nr. 7, S. 1207 – 1220
-
Toll interacting protein gene polymorphisms in patients with systemic sclerosis : association with interstitial lung disease, outcome, and survivalIn: Frontiers in Medicine, Jg. 12, 2025, 1584014DOI, Online Volltext (Open Access)
-
‘Diagnosis and Treatment of Hypersensitivity Pneumonitis’ S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical ImmunologyIn: Respiration: International Journal of Thoracic Medicine, Jg. 104, 2025, Nr. 7, S. 485 – 528DOI (Open Access)
-
Agreement between local and central anti-synthetase antibodies detection : results from the Classification Criteria of Anti-Synthetase Syndrome project biobankIn: Clinical and Experimental Rheumatology, Jg. 42, 2024, Nr. 2, S. 277 – 287DOI (Open Access)
-
CT-based body composition analysis and pulmonary fat attenuation volume as biomarkers to predict overall survival in patients with non-specific interstitial pneumoniaIn: European Radiology Experimental, Jg. 8, 2024, Nr. 1, 114DOI (Open Access)
-
Diagnostik und Therapie der exogen-allergischen Alveolitis : S2k-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. und der Deutschen Gesellschaft für Allergologie und klinische Immunologie e. V.In: Pneumologie, Jg. 78, 2024, Nr. 12, S. 963 – 1002
-
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosisIn: European Respiratory Journal (ERJ), Jg. 64, 2024, Nr. 5, 2400725DOI (Open Access)
-
Fully automatic quantification of pulmonary fat attenuation volume by CT : An exploratory pilot studyIn: European Radiology Experimental, Jg. 8, 2024, Nr. 1, 139DOI (Open Access)
-
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease with and without Pulmonary Hypertension on Survival : A Large Cohort Study of the German Network for Systemic SclerosisIn: Chest, Jg. 165, 2024, Nr. 1, S. 132 – 145DOI (Open Access)
-
Kidney manifestations of sarcoidosisIn: Journal of Autoimmunity, Jg. 149, 2024, Nr. 12, 103207DOI (Open Access)
-
Online survey on existing sarcoidosis registries and biobanks : An ERN lung initiativeIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Jg. 41, 2024, Nr. 4, e2024063DOI (Open Access)
-
Pathogenesis-driven treatment of primary pulmonary alveolar proteinosisIn: European Respiratory Review (ERR), Jg. 33, 2024, Nr. 173, 240064DOI (Open Access)
-
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses : S2k Guideline of the German Respiratory SocietyIn: Respiration: International Journal of Thoracic Medicine, Jg. 103, 2024, Nr. 12, S. 782 – 810DOI (Open Access)
-
Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM), Jg. 210, 2024, Nr. 4, S. 435 – 443
-
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis : A German and Japanese cohort studyIn: Respiratory Research, Jg. 25, 2024, Nr. 1, 405DOI (Open Access)
-
Therapie der Sarkoidose : Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)In: Pneumologie, Jg. 78, 2024, Nr. 3, S. 151 – 166
-
Anti-acid therapy in SSc-associated interstitial lung disease : long-term outcomes from the German Network for Systemic SclerosisIn: Rheumatology, Jg. 62, 2023, Nr. 9, S. 3067 – 3074DOI (Open Access)
-
COVID-19 in patients with pulmonary alveolar proteinosis : A European multicentre studyIn: ERJ Open Research, Jg. 9, 2023, Nr. 1, 00199-2022DOI (Open Access)
-
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease : Long-term outcomes from the German Network for Systemic Sclerosis-caution is key in interpreting retrospective data: ReplyIn: Rheumatology, Jg. 62, 2023, Nr. 12, S. e351 – e352
-
Current and Future Treatment Landscape for Idiopathic Pulmonary FibrosisIn: Drugs, Jg. 83, 2023, Nr. 17, S. 1581 – 1593DOI (Open Access)
-
Erratum : Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler FibrosenIn: Pneumologie, Jg. 77, 2023, Nr. 2, S. e1
-
European Respiratory Society statement on familial pulmonary fibrosisIn: European Respiratory Journal (ERJ), Jg. 61, 2023, Nr. 3, 2201383DOI (Open Access)
-
Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trialIn: European Respiratory Journal (ERJ), Jg. 62, 2023, Nr. 4DOI (Open Access)
-
Genetic and geographic influence on phenotypic variation in European sarcoidosis patientsIn: Frontiers in Medicine, Jg. 10, 2023, 1218106DOI (Open Access)
-
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare VariantsIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM), Jg. 207, 2023, Nr. 9, S. 1194 – 1202DOI, Online Volltext (Open Access)
-
Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD) : Rationale, aims and design of a nationwide prospective registryIn: BMC Pulmonary Medicine, Jg. 23, 2023, Nr. 1, 64DOI (Open Access)
-
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesotheliomaIn: Lung Cancer, Jg. 185, 2023, 107360DOI (Open Access)
-
Lung cancer in patients with idiopathic pulmonary fibrosis : A retrospective multicentre study in EuropeIn: Respirology, Jg. 28, 2023, Nr. 1, S. 56 – 65
-
MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosisIn: Respirology, Jg. 28, 2023, Nr. 5, S. 455 – 464
-
Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen : S2k-Leitline der Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V.In: Pneumologie, Jg. 77, 2023, Nr. 2, S. 94 – 119
-
Pulmonary alveolar proteinosis - current and future therapeutical strategiesIn: Current Opinion in Pulmonary Medicine, Jg. 29, 2023, Nr. 5, S. 465 – 474
-
S1-Leitlinie Interdisziplinäre Diagnostik interstitieller Lungenerkrankungen im ErwachsenenalterIn: Pneumologie, Jg. 77, 2023, Nr. 5, S. 269 – 302DOI (Open Access)
-
SARS-CoV-2-Infektion und interstitielle Lungenerkrankungen : Positionspapier der Deutschen Gesellschaft für Pneumologie und BeatmungsmedizinIn: Pneumologie, Jg. 77, 2023, Nr. 3, S. 143 – 157
-
Sarkoidose : Internationale versus deutsche Leitlinien zur Behandlung der SarkoidoseIn: Zeitschrift für Pneumologie, Jg. 20, 2023, Nr. 6, S. 325 – 332
-
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung DiseaseIn: Journal of Clinical Medicine (JCM), Jg. 12, 2023, Nr. 3, 1173DOI (Open Access)
-
Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 PneumoniaIn: Journal of Clinical Medicine (JCM), Jg. 12, 2023, Nr. 21, 6772DOI, Online Volltext (Open Access)
-
Thoracic pain in patients with chronic interstitial lung disease : an underestimated symptomIn: Frontiers in Medicine, Jg. 10, 2023, 1147555DOI, Online Volltext (Open Access)
-
A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial PneumoniaIn: Pneumologie, Jg. 76, 2022, Nr. 01, S. 25 – 34DOI (Open Access)
-
Communicating with patients with idiopathic pulmonary fibrosis : can we do it better?In: ERJ Open Research, Jg. 8, 2022, Nr. 1, 00422-2021DOI (Open Access)
-
Comparison of a 22G Crown-Cut Needle with a Conventional 22G Needle with EBUS Guidance in Diagnosis of SarcoidosisIn: Lung, Jg. 200, 2022, Nr. 5, S. 633 – 641DOI (Open Access)
-
Defining anti-synthetase syndrome: a systematic literature reviewIn: Clinical and Experimental Rheumatology, Jg. 40, 2022, Nr. 2, S. 309 – 319DOI (Open Access)
-
ERS International Congress 2021 : Highlights from the Interstitial Lung Diseases AssemblyIn: ERJ Open Research, Jg. 8, 2022, Nr. 2, 640DOI (Open Access)
-
Genetic testing in interstitial lung disease : An international surveyIn: Respirology, Jg. 27, 2022, Nr. 9, S. 747 – 757
-
IL-9 and IL-9 receptor expression in lymphocytes from bronchoalveolar lavage fluid of patients with interstitial lung diseaseIn: Immunobiology, Jg. 227, 2022, Nr. 5, 152258
-
Idiopathic pulmonary fibrosis : Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burdenIn: Respirology, Jg. 27, 2022, Nr. 1, S. 66 – 75DOI (Open Access)
-
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis An International Working Group PerspectiveIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM), Jg. 206, 2022, Nr. 3, S. 247 – 259
-
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung DiseasesIn: Advances in Therapy, Jg. 39, 2022, Nr. 7, S. 3392 – 3402DOI (Open Access)
-
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesIn: Respirology, Jg. 27, 2022, Nr. 4, S. 294 – 300DOI (Open Access)
-
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary FibrosisIn: The New England Journal of Medicine, Jg. 387, 2022, Nr. 8, S. 761 – 762DOI (Open Access)
-
Chest radiography or computed tomography for COVID-19 pneumonia? : Comparative study in a simulated triage settingIn: European Respiratory Journal (ERJ), Jg. 58, 2021, Nr. 3, 2004188DOI (Open Access)
-
ERS clinical practice guidelines on treatment of sarcoidosisIn: European Respiratory Journal (ERJ), Jg. 58, 2021, Nr. 6, 2004079DOI (Open Access)
-
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbiditiesIn: Respiratory Research, Jg. 22, 2021, Nr. 1, S. 125DOI (Open Access)
-
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)In: Annals of the Rheumatic Diseases (ARD), Jg. 80, 2021, Nr. 2, S. 143 – 150DOI (Open Access)
-
Misconceptions regarding symptoms of sarcoidosisIn: The Lancet Respiratory Medicine, Jg. 9, 2021, Nr. 8, S. 816 – 818
-
Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis : A Multinational European SurveyIn: Frontiers in Medicine, Jg. 8, 2021, 711194DOI (Open Access)
-
Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease : Where to go from here?In: European Respiratory Review (ERR), Jg. 30, 2021, Nr. 160, 210026DOI (Open Access)
-
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF) : A double-blind, randomised, placebo-controlled, phase 2b trialIn: The Lancet Respiratory Medicine, Jg. 9, 2021, Nr. 5, S. 476 – 486DOI, Online Volltext (Open Access)
-
Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPFIn: Orphanet Journal of Rare Diseases, Jg. 16, 2021, Nr. 1, 111DOI, Online Volltext (Open Access)
-
S2K Guideline for Diagnosis of Idiopathic Pulmonary FibrosisIn: Respiration: International Journal of Thoracic Medicine, Jg. 100, 2021, Nr. 3, S. 238 – 271DOI (Open Access)
-
Sprachliche Validierung des Fibrose-Fragebogens zur Erfassung der Lebensqualität bei Patienten mit idiopathischer Lungenfibrose und idiopathischer nichtspezifischer interstitieller PneumonieIn: Pneumologie, Jg. 75, 2021, Nr. 10, S. 753 – 760
-
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey : international survey and call for consensusIn: ERJ Open Research, Jg. 7, 2021, Nr. 1, S. 00529 – 02020DOI (Open Access)
-
Unclassifiable, or simply unclassified interstitial lung disease?In: Current Opinion in Pulmonary Medicine, Jg. 27, 2021, Nr. 5, S. 405 – 413
-
Adiponectin and leptin levels in idiopathic pulmonary fibrosis : A new method for BAL and serum assessmentIn: Immunobiology, Jg. 225, 2020, Nr. 5, 151997
-
Azathioprine for Connective Tissue Disease-Associated Interstitial Lung DiseaseIn: Respiration: International Journal of Thoracic Medicine, Jg. 99, 2020, Nr. 8, S. 628 – 636
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer (EJC), Jg. 131, 2020, S. 18 – 26
-
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy : a systematic review and meta-analysisIn: BMC Pulmonary Medicine, Jg. 20, 2020, S. 128DOI (Open Access)
-
Ganzlungenlavage bei pulmonaler Alveolarproteinose - Schritt für SchrittIn: Pneumologie, Jg. 74, 2020, Nr. 10, S. 660 – 664
-
Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort : Preliminary ResultsIn: The Journal of Heart and Lung Transplantation, Jg. 39, 2020, Nr. 4, S. S305 – S306
-
Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosisIn: The New England Journal of Medicine, Jg. 383, 2020, Nr. 17, S. 1635 – 1644DOI (Open Access)
-
Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease : A comprehensive reviewIn: Biomarkers in Medicine, Jg. 14, 2020, Nr. 8, S. 675 – 682
-
Looking into the future of sarcoidosis : What is next for treatment?In: Current Opinion in Pulmonary Medicine, Jg. 26, 2020, Nr. 5, S. 598 – 607
-
S2K-Leitlinie zur Diagnostik der idiopathischen LungenfibroseIn: Pneumologie, Jg. 74, 2020, Nr. 5, S. 263 – 293
-
Serum KL-6 concentrations as a novel biomarker of severe COVID-19In: Journal of Medical Virology, Jg. 92, 2020, Nr. 10, S. 2216 – 2220DOI, Online Volltext (Open Access)
-
Shedding light on developmental drugs for idiopathic pulmonary fibrosisIn: Expert Opinion on Investigational Drugs, Jg. 29, 2020, Nr. 8, S. 797 – 808DOI (Open Access)
-
Therapie der systemischen Sklerose-assoziierten interstitiellen LungenerkrankungIn: Zeitschrift für Rheumatologie, Jg. 79, 2020, Nr. 3, S. 294 – 303DOI (Open Access)
-
Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen FibroseIn: Der Pneumologe, Jg. 17, 2020, Nr. 3, S. 186 – 196DOI (Open Access)
-
Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis : German and Japanese Cohort StudyIn: Journal of Clinical Medicine (JCM), Jg. 8, 2019, Nr. 12, 2069DOI (Open Access)
-
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trialsIn: European Respiratory Journal (ERJ), Jg. 54, 2019, Nr. 3, S. 1801797DOI (Open Access)
-
Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipientsIn: Transplant Immunology, Jg. 52, 2019, S. 40 – 44
-
Correction to: The burden of sarcoidosis symptoms from a patient perspectiveIn: Lung, Jg. 197, 2019, Nr. 2, S. 163DOI (Open Access)
-
Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)In: Der Pneumologe, Jg. 16, 2019, Nr. 1, S. 39DOI (Open Access)
-
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time CourseIn: Journal of Clinical Medicine (JCM), Jg. 8, 2019, Nr. 11, 2013DOI (Open Access)
-
Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations : Results of a multicenter international studyIn: The Journal of Rheumatology, Jg. 46, 2019, Nr. 3, S. 279 – 284DOI (Open Access)
-
Quantitative lipidomics in pulmonary alveolar proteinosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM), Jg. 200, 2019, Nr. 7, S. 881 – 887
-
Research highlights from the 2018 ERS International Congress : interstitial lung diseasesIn: ERJ Open Research, Jg. 5, 2019, Nr. 1, S. 00215 – 02018DOI (Open Access)
-
Shaping the future of an ultra-rare disease : unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosisIn: Current Opinion in Pulmonary Medicine, Jg. 25, 2019, Nr. 5, S. 450 – 458
-
The Burden of Sarcoidosis Symptoms from a Patient PerspectiveIn: Lung, Jg. 197, 2019, Nr. 2, S. 155 – 161DOI (Open Access)
-
The characterisation of interstitial lung disease multidisciplinary team meetings : A global studyIn: ERJ Open Research, Jg. 5, 2019, Nr. 2, S. 00209 – 02018DOI (Open Access)
-
Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial PneumoniaIn: Respiration: International Journal of Thoracic Medicine, Jg. 98, 2019, Nr. 1, S. 29 – 37DOI, Online Volltext (Open Access)
-
Die „Rheumalunge“ in der Computertomographie : radiologische Manifestationen der rheumatoiden ArthritisIn: Der Pneumologe, Jg. 15, 2018, Nr. 6, S. 419 – 427
-
Differenzialdiagnose interstitieller LungenerkrankungenIn: Der Pneumologe, Jg. 15, 2018, Nr. 6, S. 413 – 418
-
European Respiratory Society International Congress 2017 : Highlights from the Clinical AssemblyIn: ERJ Open Research, Jg. 4, 2018, Nr. 1, S. 00134 – 02017DOI (Open Access)
-
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis : Uncertainties and ControversiesIn: Respiration: International Journal of Thoracic Medicine, Jg. 96, 2018, Nr. 6, S. 571 – 587
-
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary FibrosisIn: Respiration: International Journal of Thoracic Medicine, Jg. 96, 2018, Nr. 4, S. 314 – 322
-
Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen - klinische Sektion der DGPIn: Pneumologie, Jg. 72, 2018, Nr. 6, S. 446 – 457
-
Phenotypes of organ involvement in sarcoidosisIn: European Respiratory Journal (ERJ), Jg. 51, 2018, Nr. 1, S. 1700991DOI (Open Access)
-
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisIn: Respiration: International Journal of Thoracic Medicine, Jg. 95, 2018, Nr. 5, S. 317 – 326DOI (Open Access)
-
Timing of onset affects arthritis presentation pattern in antisynthetase syndromeIn: Clinical and Experimental Rheumatology, Jg. 36, 2018, Nr. 1, S. 44 – 49
-
Epidemiologie und klinisches Erscheinungsbild der SarkoidoseIn: Klinische Monatsblätter für Augenheilkunde, Jg. 234, 2017, Nr. 6, S. 790 – 795
-
Idiopathic pleuroparenchymal fibroelastosis (PPFE) : A case study of a rare entityIn: Revista Portuguesa de Pneumologia (English Edition), Jg. 23, 2017, Nr. 6, S. 352 – 355DOI (Open Access)
-
Therapeutic targets in idiopathic pulmonary fibrosisIn: Respiratory Medicine, Jg. 131, 2017, S. 49 – 57
-
Facts and promises on lung biomarkers in interstitial lung diseasesIn: Expert Review of Respiratory Medicine, Jg. 9, 2015, Nr. 4, S. 437 – 457
-
Update on therapeutic management of idiopathic pulmonary fibrosisIn: Therapeutics and Clinical Risk Management, Jg. 11, 2015, S. 359 – 370DOI (Open Access)
-
Chronic Hypersensitivity PneumonitisIn: Clinics in Chest Medicine, Jg. 33, 2012, Nr. 1, S. 151 – 163
-
Diagnostic approach to interstitial pneumonias in a single centre : report on 88 casesIn: Diagnostic Pathology, Jg. 7, 2012, S. 160DOI, Online Volltext (Open Access)
-
Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levelsIn: Respiratory Medicine, Jg. 106, 2012, Nr. 12, S. 1756 – 1764
-
Hypersensitivity PneumonitisIn: Immunology and Allergy Clinics of North America, Jg. 32, 2012, Nr. 4, S. 537 – 556
-
KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndromeIn: Orphanet Journal of Rare Diseases, Jg. 7, 2012, Nr. 1, S. 99DOI (Open Access)
-
Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosisIn: European Respiratory Journal (ERJ), Jg. 40, 2012, Nr. 6, S. 1468 – 1474
-
Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantationIn: The Journal of Heart and Lung Transplantation, Jg. 30, 2011, Nr. 12, S. 1374 – 1380
-
Lungensarkoidose : Diagnostik und TherapieIn: Gynäkologische Praxis, Jg. 35, 2011, Nr. 3, S. 473 – 482
-
Lungensarkoidose : Diagnostik und TherapieIn: Tägliche Praxis, Jg. 52, 2011, Nr. 3, S. 463 – 472
-
Pulmonary alveolar proteinosis : New insights from a single-center cohort of 70 patientsIn: Respiratory Medicine, Jg. 105, 2011, Nr. 12, S. 1908 – 1916
-
Surfactant protein D and KL-6 serum levels in systemic sclerosis: Correlation with lung and systemic involvementIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Jg. 28, 2011, Nr. 1, S. 27 – 33
-
Treatment of pulmonary fibrosis : New substances and new interventionsIn: Der Internist, Jg. 52, 2011, Nr. 12, S. 1422 – 1428
-
Angiogenic and angiostatic chemokines in idiopathic pulmonary fibrosis and granulomatous lung diseaseIn: Respiration: International Journal of Thoracic Medicine, Jg. 80, 2010, Nr. 5, S. 372 – 378DOI (Open Access)
-
Diagnostic modalities in sarcoidosis: BAL, EBUS, and PETIn: Seminars in Respiratory and Critical Care Medicine, Jg. 31, 2010, Nr. 4, S. 404 – 408
-
Correction: Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosisIn: Frontiers in Medicine. Lausanne: Frontiers Media, Jg. 12, 2025DOI (Open Access)
-
Pulmonale Manifestationen der rheumatischen ErkrankungenIn: Zeitschrift für Pneumologie. Berlin: Springer, Jg. 22, 2025, Nr. 4, S. 175 – 176DOI (Open Access)
-
Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? : Many pole positions, not yet the final winnerIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 63, 2024, Nr. 1, 2301982
-
Interstitielle LungenerkrankungenIn: Zeitschrift für Pneumologie. Berlin: Springer, Jg. 20, 2023, Nr. 6, S. 297 – 299DOI (Open Access)
-
IntroductionIn: Sarcoidosis / Bonella, Francesco; Culver, Daniel A.; Israël-Biet, Dominique (Hrsg.). Sheffield: European Respiratory Society, 2022, S. x – xiii
-
Targeted therapy for pulmonary alveolar proteinosis: the time is nowIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 59, 2022, Nr. 4, 2102971DOI (Open Access)
-
The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis : Is it of diagnostic value?In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. 2, S. 2001534DOI (Open Access)
-
When the Game Changes : Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 PandemicIn: Chest. Amsterdam: Elsevier, Jg. 158, 2020, Nr. 3, S. 892 – 895DOI, Online Volltext (Open Access)
-
Accurate Classification of Axial CT Images as Diffuse Cystic Lung Disease and Emphysema Using Artificial Intelligence and Machine Learning TechniquesIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A2940 – A2940
-
Clinical Relevance of Lipid-laden Macrophages in the Bronchoalveolar Lavage (BAL) Fluid of Patients With Interstitial Lung Disease (ILD)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A3525 – A3525
-
Development and Validation of Machine-learned Algorithms for Diagnosing ASMD Among Patients With Unexplained ILDIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A2914 – A2914
-
Dipnech : Clinical Characteristics of an International Case SeriesIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A1804 – A1804
-
Lung Transplantation for Pulmonary Alveolar Proteinosis : A Retrospective International Multicenter AnalysisIn: The Journal of Heart and Lung Transplantation. Amsterdam: Elsevier, Jg. 44, 2025, Nr. Suppl. 4, S. S126
-
Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) : Results From the IMPALA-2 Phase 3 Clinical TrialIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A1129 – A1129
-
Reversal of Interstitial Lung Disease in Children and Adults With Chronic Acid Sphingomyelinase Deficiency Treated With Olipudase Alfa Enzyme Replacement TherapyIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A1134 – A1134
-
The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A1811 – A1811
-
Toll Interacting Protein (TOLLIP) Serum Levels in Patients With Systemic Sclerosis Associated ILD (SSC-ILD) : A New Biomarker?In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 211, 2025, Nr. Suppl., S. A3560 – A3560
-
Automated 3D Body Composition Analysis (BCA) as a Potential Predictor of Overall Survival in Patients With Nonspecific Interstitial Pneumonia (NSIP)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 209, 2024, Nr. Supplement, A1320
-
Biomarkers extracted by fully automated body composition analysis (BCA) from chest CT in patients with non-specific interstitial pneumonia (NSIP) : correlation with survival
64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 20.–23.03.2024, Mannheim, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 78, 2024, Nr. Suppl. 1, S. S93 -
Charakteristika und Behandlung von Patienten mit fibrosierender interstitieller Lungenerkrankung in der klinischen Praxis : INSIGHTS-ILD Register
64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 20.–23. März 2024, Mannheim, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 78, 2024, Nr. Suppl. 1, S. S75 – S76 -
Children’s ILDs survivors in adulthood : a European StudyIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Suppl. 68, OA1066DOI (Open Access)
-
Clinical relevance of diffusing lung capacity for carbon monoxide (DLCO) in patients with acid sphingomyelinase disease (ASMD) : a post-hoc analysisIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Suppl. 68, PA4285DOI (Open Access)
-
Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references
ERS Congress 2024, 7–11 September 2024, Vienna, Austria,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Supplement 68, PA673 -
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) : An international case seriesIn: Journal of Neuroendocrinology: Wiley, Jg. 36, 2024, Nr. Suppl. 1, S. 123
-
From body composition to pulmonary fat attenuation volume : evaluation of new CT-based biomarkers to predict the overall survival in patients with non-specific interstitial pneumonia (NSIP).In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Suppl. 68DOI (Open Access)
-
Olipudase alfa enzyme replacement therapy reverses interstitial lung disease in adults with acid sphingomyelinase deficiency : Long-term pulmonary outcomes of the ASCEND trialIn: Molecular Genetics and Metabolism. Amsterdam; Orlando, Fla.: Elsevier, Jg. 141, 2024, Nr. 2, 108075
-
Prognostic relevance of autoantibodies in patients with hypersensitivity pneumonitis (HP) : A German multicentre study
European-Respiratory-Society Congress (ERS); SEP 07-11, 2024; Vienna, Austria,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Suppl. 68, PA2453 -
RCT Abstract - Inhaled molgramostim improves pulmonary gas exchange and respiratory health-related quality of life (HRQoL) in patients with autoimmune pulmonary alveolar proteinosis (aPAP) : Results from IMPALA-2In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 64, 2024, Nr. Suppl. 68DOI (Open Access)
-
Toll interacting protein (TOLLIP) gene polymorphisms in patients with systemic sclerosis (SSc) associated interstitial lung disease (ILD) : association with outcome and survivalIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 209, 2024, Nr. Suppl., A1321DOI (Open Access)
-
Association of ORMDL3 Polymorphisms With Disease Outcomes and Severity in Patients With Pulmonary Alveolar Proteinosis (PAP)
American Thoracic Society 2023 International Conference, May 19-24, 2023, Washington, DC,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 207, 2023, Nr. Supplement: A38, Advancing our Understanding and Treatment of ILD, A4275 -
Biomarkers Extracted by Fully Automated Body Composition Analysis From Chest CT Correlate With Survival in Idiopathic Pulmonary Fibrosis (IPF)
American Thoracic Society 2023 International Conference, May 19-24, 2023, Washington, DC,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 207, 2023, Nr. Supplement: A38, Advancing our Understanding and Treatment of ILD, A1500 -
Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Data From the INBUILD Trial
American Thoracic Society 2023 International Conference, May 19-24, 2023, Washington, DC,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 207, 2023, Nr. Supplement: A38, Advancing our Understanding and Treatment of ILD, A1112 -
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease : Data from INBUILD- ONIn: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 75, 2023, Nr. Suppl. 9, S. 4260 – 4262
-
Die Etablierung einer durchflusszytometrischen Multiparameter-Analyse der BAL und ihre Validierung durch Korrelation mit den Befunden der lichtmikroskopischen Routinediagnostik
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S85 – S86 -
Die Komplexizität der Diagnostik pulmonaler kavernöser Prozesse : Ein pneumologisch – rheumatolgischer Fallbericht
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. 86 – S87 -
Die durchflusszytometrische Analyse von T-Lymphozytensubpopulationen in der bronchoalveolären Lavage (BAL) bei interstitiellen Lungenerkrankungen
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S86 -
Effects of Nintedanib on Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis : Subgroup Analyses of the INBUILD Trial
American Thoracic Society 2023 International Conference, May 19-24, 2023, Washington, DC,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 207, 2023, A1128 , Supplement: A38, Advancing our Understanding and Treatment of ILD -
Effects of nintedanib on circulating biomarkers in patients with progressive fibrosing autoimmune disease-related interstitial lung diseases
European Congress of Rheumatology (EULAR); MAY 31-JUN 03, 2023; Milan, ITALY,In: Annals of the Rheumatic Diseases (ARD). London: BMJ Publishing Group, Jg. 82, 2023, Nr. Suppl. 1, S. 722 – 722DOI (Open Access) -
KL-6 is a potential diagnostic biomarker for pleural mesothelioma
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S106 – S107 -
Progrediente Pulmonale Fibrose (PPF) bei Patienten mit exogen allergischer Alveolitis
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S102 -
Prospektive randomisierte Studie zum Vergleich zweier Methoden der transbronchialen Kryobiopsie bei interstitiellen Lungenerkrankungen
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S49 -
Reversal of interstitial lung disease after olipudase alfa enzyme replacement therapy in adults with acid sphingomyelinase deficiency
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, OA3281 -
Association of mUC5B rs35705950 minor allele with age and survival in European patients with Idiopathic Pulmonary FibrosisIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. 66, 1044
-
COVID-19 in patients with Pulmonary Alveolar Proteinosis : A European multicenter study
ERS International Congress 2022 ; 4-6 September 2022, Barcelona, Spain and online,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. Supplement 66 -
Cellular activities of factor XII in lung fibrosis
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S42 -
Comparison of a new Punch Needle with a conventional 22-gauge Needle in EBUS-TBNA in Patients with suspected Sarcoidosis
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S44 -
Continued improvement in pulmonary outcomes in 3 clinical trials of olipudase alfa in children and adults with chronic acid sphingomyelinase deficiency treated for 2 to 6.5 years
WORLDSymposiumTM 2022, 07.-11.02.2022, Virtual,In: Molecular Genetics and Metabolism. Amsterdam; Orlando, Fla.: Elsevier, Jg. 135, 2022, Nr. 2, S. S108 -
Continued nintedanib treatment in patients with progressive fibrosing ILDs : Interim analysis of INBUILD-ONIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. 66, 604
-
Effects of Nintedanib on Circulating Biomarkers in Subjects with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
International Conference of the American Thoracic Society (ATS) 2022 ; May 13-18, 2022, San Francisco, CA, USA,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 205, 2022, Nr. Supplement, A3520DOI (Open Access) -
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S52 -
Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burdenIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. 66, 615
-
ORMDL3 gene polymorphisms in patients with pulmonary alveolar proteinosis (PAP) and interstitial lung diseases (ILDs) : preliminary results
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S56 -
Safety and tolerability of inhaled molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP)
ERS International Congress ; 4-6 September 2022, Barcelona, Spain and online,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. Supplement 66 -
Serum KL-6 improves prediction of progressive phenotype (PP) at one year independently of underlying interstitial lung disease (ILD) : Results from the VAMOS studyIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 60, 2022, Nr. 66, 1274
-
Sustained Improvement of Interstitial Lung Disease Following Enzyme Replacement Therapy with Olipudase Alfa in Children and Adults with Chronic Acid Sphingomyelinase Deficiency
International Conference of the American Thoracic Society (ATS) 2022 ; May 13-18, 2022, San Francisco, CA, USA,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 205, 2022, Nr. Supplement, A5319DOI (Open Access) -
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, 2021, OA4240DOI (Open Access)
-
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib : Sub-Study of the SENSCIS TrialIn: Pneumologie. Stuttgart: Thieme, Jg. 75, 2021, Nr. Suppl. 1, 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V., 02.–05.06.2021, Leipzig digital, S. S24 – S25
-
Comparison of a 22G crown-cut needle with a conventional 22G needle with EBUS guidance in diagnosis of sarcoidosisIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 58, 2021, Nr. Suppl. 65, PA2454DOI (Open Access)
-
Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V., 02.–05.06.2021, Leipzig digital,In: Pneumologie. Stuttgart: Thieme, Jg. 75, 2021, Nr. Suppl. 1, S. S25 – S26 -
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases : Data from INBUILD-ONIn: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 73, 2021, Nr. Suppl. 9, S. 372 – 373
-
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ONIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 58, 2021, Nr. Suppl. 65, PA2538DOI (Open Access)
-
Prevalence and quantification of thoracic pain (TP) through quantitative sensory testing (QST) in patients with chronic interstitial lung disease (cILD)In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 58, 2021, Nr. Suppl. 65, PA2343
-
Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases : Pooled data from four trialsIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 58, 2021, Nr. Suppl. 65, PA2539DOI (Open Access)
-
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infectionIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 58, 2021, Nr. Suppl. 65, PA655DOI (Open Access)
-
Berufliche bedingte EAA und die problematische Suche nach dem Auslöser
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 74, 2020, Nr. Suppl. 1, S. S122 -
Burden of idiopathic pulmonary fibrosis (IPF) on quality of life (QoL), work productivity, and healthcare useIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 23, 2020, Nr. Suppl. 2, S. 732DOI (Open Access)
-
Clinical burden of idiopathic pulmonary fibrosis (IPF) : physician and patient perceptionIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
ERS Virtual Congress 2020,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access) -
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 74, 2020, Nr. Suppl. 1, S. S90 – S91 -
Does anti-acid treatment influence disease progression in systemic sclerosis interstitial lung disease (SSC-ILD)? : Data from the german SSC-networkIn: Annals of the Rheumatic Diseases (ARD). London: BMJ Publishing Group, Jg. 79, 2020, Nr. Suppl. 1, S. 1585
-
Effects of nintedanib in patients with IPF : subgroup analysis by Charlson Comorbidity Index (CCI)In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC : further analyses of the INBUILD trialIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Multiple ComorbiditiesIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 201, 2020, S. A4549
-
Efficacy and safety of nintedanib in the elderly patient with IPF
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 74, 2020, Nr. Suppl. 1, S. S100 -
Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Nintedanib and Sildenafil : Data from the INSTAGE Trial
ATS 2020 International Conference, 15.-20. Mai 2020, Philadelphia, USA - abgesagt,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 201, 2020, S. A4049 -
Idiopathic pulmonary fibrosis (IPF) : the patient journeyIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Klinische Nutzbarkeit eines mit Serum KL-6 modifizierten GAP-Indexes bei Patienten mit interstitiellen Lungenerkrankungen (ILD)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 74, 2020, Nr. Suppl. 1, S. S10 -
Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone : phase IV clinical trialIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access)
-
Potential Clinical Utility of Serum KL-6 for Improving the GAP-Staging in Patients with Interstitial Lung Diseases (ILD)
ATS 2020 International Conference, 15.-20. Mai 2020, Philadelphia, USA - abgesagt,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 201, 2020, S. A4037 -
The DIAMORFOSIS (Diagnosis and Management of Lung Cancer and Fibrosis) Survey
ATS 2020 International Conference, 15.-20. Mai 2020, Philadelphia, USA - abgesagt,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 201, 2020, S. A2579 -
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD)
ERS International Congress 2020,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64DOI (Open Access) -
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases : Subgroup with Autoimmune Diseases
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28. März 2020 (verschoben auf 2021); Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 74, 2020, Nr. Suppl. 1, S. S61 – S62 -
Efficacy and safety of nintedanib in the elderly patient with IPFIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 54, 2019, Nr. Suppl. 63, S. PA1353DOI (Open Access)
-
Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 54, 2019, Nr. Suppl. 63, S. RCT1879DOI (Open Access)
-
Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPFIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 54, 2019, Nr. Suppl. 63, S. PA5370DOI (Open Access)
-
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassayIn: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 54, 2019, Nr. Suppl. 63, S. PA4697DOI (Open Access)
-
THU0339 Pulmonary Involvement and Outcome in Systemic Sclerosis (SSC) – ILD-PH as an Important SubsetIn: Annals of the Rheumatic Diseases (ARD). London: BMJ Publishing Group, Jg. 78, 2019, Nr. Suppl. 2, S. 451DOI (Open Access)
-
Cardiovascular safety of nintedanib in subgroups by baseline cardiovascular risk
Annual Scientific Meeting of the Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) ; 23–27 March 2018, Adelaide,In: Respirology. Hoboken: Wiley-Blackwell - STM, Jg. 23, 2018, Nr. Suppl. 1, S. 101DOI (Open Access) -
Clinical Relevance of Antinuclear Antibodies (ANA) in Patients with Hypersensitivity Pneumonitis (HP) : A Single Centre Experience
International Conference of the American Thoracic Society 2018 ; ATS 2018 ; May 18-23, 2018. San Diego,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 197, 2018, Nr. 9, abstract issue, S. A3019 -
Predicted Versus Observed Mortality in Clinical Trials of Nintedanib in Idiopathic Pulmonary Fibrosis (IPF)
International Conference of the American Thoracic Society 2018 ; ATS 2018 ; May 18-23, 2018, San Diego,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 197, 2018, Nr. 9, abstract issue, S. A2534 -
IgG4-related disease as an unexpected cause of hemoptysisIn: Rare and Interstitial Lung Diseases: Clinical Cases and Real-World Discussions. Philadelphia: Elsevier, 2025, S. 207 – 218
-
Pulmonary alveolar microlithiasis : An ultra-rare diseaseIn: Rare and Interstitial Lung Diseases: Clinical Cases and Real-World Discussions. Philadelphia: Elsevier, 2024, S. 171 – 182
-
BAL findings in interstitial lung diseaseIn: Bronchoalveolar Lavage in Basic Research and Clinical Medicine / Schildgen, Oliver; Schildgen, Verena; Brockmann, Michael (Hrsg.). Boca Raton: CRC Press, 2023, S. 66 – 93
-
Pulmonary Langerhans Cell Histiocytosis and Pulmonary LymphangioleiomyomatosisIn: Airway Diseases / Cingi, Cemal; Yorgancıoğlu, Arzu; Muluk, Nuray Bayar; Cruz, Alvaro A. (Hrsg.). Cham: Springer International Publishing, 2023, S. 1839 – 1860
-
Pulmonary sarcoidosisIn: Sarcoidosis / Bonella, Francesco; Culver, Daniel A.; Israël-Biet, Dominique (Hrsg.). Sheffield: European Respiratory Society, 2022, S. 122 – 141
-
Rare and Interstitial Lung Diseases : Clinical Cases and Real-World DiscussionsPhiladelphia: Elsevier, 2024
-
SarcoidosisSheffield: European Respiratory Society, 2022
(European Respiratory Society Monograph ; 96) -
Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs : Analysis from the "Classification Criteria for Anti-synthetase Syndrome (CLASS)" Project Database
ACR Convergence 2024, November 15–19, 2024, Washington, DC, USA,In: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 76, 2024, Nr. S9, S. 2361 – 2363 -
Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome : An Analysis of the CLASS Project Database
ACR Convergence 2024, November 15–19, 2024, Washington, DC, USA,In: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 76, 2024, Nr. S9, S. 4168 – 4171 -
Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD) : Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
ACR Convergence 2024, November 15–19, 2024, Washington, DC, USA,In: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 76, 2024, Nr. S9, S. 646 – 649 -
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome : Analysis from the "Classification Criteria for Anti-synthetase Syndrome (CLASS)" Project Database
ACR Convergence 2024, November 15–19, 2024, Washington, DC, USA,In: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 76, 2024, Nr. S9, S. 649 – 652 -
Clinical Characteristics of Anti-Synthetase Syndrome : Analysis from the Class Project
EULAR 2024 Congress, 12-15 June, 2024, Vienna, Austria,In: Annals of the Rheumatic Diseases (ARD). London: BMJ Publishing Group, Jg. 83, 2024, Nr. Supplement 1, S. 617 – 618 -
Continued nintedanib treatment in patients with progressive pulmonary fibrosis : data from INBUILD-ON
64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 20.–23. März 2024, Mannheim, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 78, 2024, Nr. Suppl. 1, S. S79 -
Die durchflusszytometrische Untersuchung von T-Lymphozytensubpopulationen in der Ganzlungen-Lavage (GLL) bei der pulmonalen Alveolarproteinose : eine Pilot-Studie
64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 20.–23.03.2024, Mannheim, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 78, 2024, Nr. Suppl. 1, S. S11 – S12 -
Different Clinical Phenotypes of Patients with Anti-synthetase Syndrome : Unsupervised Cluster Analysis in the CLASS Database
ACR Convergence 2024, November 15–19, 2024, Washington, DC, USA,In: Arthritis & Rheumatology. Hoboken: Wiley, Jg. 76, 2024, Nr. S9, S. 4210 – 4214 -
Machine learned decision tree for diagnosis of ASMD among patients with unexplained ILD
64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 20.–23. März 2024, Mannheim, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 78, 2024, Nr. Suppl. 1, S. S84 -
CT-derived biomarkers as predictors of overall survival in patients with idiopathic pulmonary fibrosis (IPF)
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA1131 -
Continued nintedanib treatment in patients with progressive pulmonary fibrosis : data from INBUILD-ON
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA2874 -
Effects of nintedanib on circulating biomarkers in patients with progressive pulmonary fibrosis : subgroups by fibrotic pattern on HRCT
International Congress of the European Respiratory Journal (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA2879 -
Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., 29.03 – 01.04.2023, Düsseldorf, Germany,In: Pneumologie. Stuttgart: Thieme, Jg. 77, 2023, Nr. S 01, S. S57 -
Flow cytometric evaluation of whole lung lavage (WLL) fluid from patients with pulmonary alveolar proteinosis (PAP) : preliminary findings
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA3946 -
Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA1139 -
Machine learned decision tree for diagnosis of ASMD among patients with unexplained ILD
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA3948 -
Prognostic value of circulating biomarkers in patients with progressive pulmonary fibrosis
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA1132 -
Progressive pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis (cHP) : a single center experience
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 62, 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA2883 -
Continued nintedanib treatment in patients with progressive fibrosing ILDs : interim analysis of INBUILD-ON
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S25 – S26 -
Effects of nintedanib in patients with idiopathic pulmonary fibrosis and varying severities of cough
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie. Stuttgart: Thieme, Jg. 76, 2022, Nr. Supplement 1, S. S20 – S21 -
Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
International Conference of the American Thoracic Society (ATS) 2022 ; May 13-18, 2022, San Francisco, CA, USA,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 205, 2022, Nr. Supplement, A2426DOI (Open Access) -
ORMDL3 Gene Polymorphisms in Patients with Pulmonary Alveolar Proteinosis (PAP) and Interstitial Lung Diseases (ILDs) : Preliminary Results
International Conference of the American Thoracic Society (ATS) 2022 ; May 13-18, 2022, San Francisco, CA, USA,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 205, 2022, Nr. Supplement, A3922DOI (Open Access) -
Effects of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Varying Severities of Cough
International Conference of the American Thoracic Society (ATS) 2021 ; May 14-19, 2021, Virtual,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM). New York: American Thoracic Society, Jg. 203, 2021, Nr. 9, Supplement, A1903DOI (Open Access)